References
- Balneaves, L. G., Alraja, A., Ziemianski, D., McCuaig, F., & Ware, M. (2018). A national needs assessment of Canadian nurse practitioners regarding cannabis for therapeutic purposes. Cannabis and Cannabinoid Research, 3(1), 66–73. https://doi.org/https://doi.org/10.1089/can.2018.0002
- Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse, 40, 22–30. https://doi.org/https://doi.org/10.3109/00952990.2013.821477
- Canadian Pharmacists’ Association. (2019). Cannabis for medical purposes: How to help patients find a safe and effective dose. https://www.pharmacists.ca/cpha-ca/assets/File/education-practice-resources/Cannabis%20Dosing%20and%20Titrating%20Final_web.pdf
- Cascini, F., Aiello, C., & Di Tanna, G. (2012). Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: Systematic review and meta-analysis. Current Drug Abuse Reviews, 5(1), 32–40. https://doi.org/https://doi.org/10.2174/1874473711205010032
- Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). European Archives of Psychiatry and Clinical Neuroscience, 269(1), 5–15. https://doi.org/https://doi.org/10.1007/s00406-019-00983-5
- Colizzi, M., & Bhattacharyya, S. (2017). Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports, 4(2), 62–74. https://doi.org/https://doi.org/10.1007/s40429-017-0142-2
- Crippa, J. A., Hallak, J. E., Machado-de-Sousa, J. P., Queiroz, R. H., Bergamaschi, M., Chagas, M. H., & Zuardi, A. W. (2013). Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report. Journal of Clinical Pharmacy and Therapeutics, 38(2), 162–164. https://doi.org/https://doi.org/10.1111/jcpt.12018
- Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: A critical review of the evidence. Human Psychopharmacology: Clinical and Experimental, 24(7), 515–523. https://doi.org/https://doi.org/10.1002/hup.1048
- Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S., Wiffen, B., Powell, J., & Murray, R. (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry, 195(6), 488–491. https://doi.org/https://doi.org/10.1192/bjp.bp.109.064220
- ElSohly, M. A., Ross, S. A., Mehmedic, Z., Arafat, R., Yi, B., & Banahan, B. F., 3rd. (2000). Potency trends of delta-9-THC and other cannabinoids in confiscated marijuana from 1980 to 1997. Journal of Forensic Sciences, 45(1), 24–30. https://doi.org/https://doi.org/10.1520/JFS14636J
- Freeman, T. P., & Lorenzetti, V. (2019). ‘Standard THC units’: A proposal to standardize dose across all cannabis products and methods of administration. Addiction. https://doi.org/https://doi.org/10.1111/add.14842
- Freeman, T. P., Morgan, C. J., Hindocha, C., Schafer, G., Das, R. K., & Curran, H. V. (2014). Just say ‘know’: How do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction, 109(10), 1686–1694. https://doi.org/https://doi.org/10.1111/add.12634
- Freeman, T., & Winstock, A. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine, 45(15), 3181–3189. https://doi.org/https://doi.org/10.1017/S0033291715001178
- Gable, R. S. (2004). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 99(6), 686–696. https://doi.org/https://doi.org/10.1111/j.1360-0443.2004.00744.x
- Hammersley, R., Ditton, J., & Main, D. (1997). Drug use and sources of drug information in a 12–16-year-old school sample. Drugs: Education, Prevention and Policy, 4(3), 231–241. https://doi.org/https://doi.org/10.3109/09687639709028545
- Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., & Walsh, S. L. (2016). Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology, 41(8), 1974–1982. https://doi.org/https://doi.org/10.1038/npp.2015.367
- Jikomes, N., & Zoorob, M. (2018). The cannabinoid content of legal cannabis in Washington State varies systematically across testing facilities and popular consumer products. Scientific Reports, 8(1), 4519. https://doi.org/https://doi.org/10.1038/s41598-018-22755-2
- Kruger, D. J., & Kruger, J. S. (2019). Medical cannabis users’ comparisons between medical cannabis and mainstream medicine. Journal of Psychoactive Drugs, 51(1), 31–36. https://doi.org/https://doi.org/10.1080/02791072.2018.1563314
- Kruger, D. J., Kruger, J. S., Wagner-Greene, V. R., Wotring, A., Castor, T. S., Blavos, A., & Glassman, T. J. (2019). Health-related behaviors, health outcomes, and health access issues among cannabis users in the Midwestern USA. Journal of Alcohol and Drug Education, 63, 8–25.
- Lamonica, L. K., Boeri, M., & Anderson, T. (2016). Gaps in medical marijuana policy implementation: Real-time perspectives from marijuana dispensary entrepreneurs, health care professionals and medical marijuana patients. Drugs: Education, Prevention and Policy, 23(5), 422–434. https://doi.org/https://doi.org/10.3109/09687637.2016.1150963
- Maa, E., & Figi, P. (2014). The case for medical marijuana in epilepsy. Epilepsia, 55(6), 783–786. https://doi.org/https://doi.org/10.1111/epi.12610
- MacCoun, R. J., & Mello, M. M. (2015). Half-baked—The retail promotion of marijuana edibles. New England Journal of Medicine, 372(11), 989–991. https://doi.org/https://doi.org/10.1056/NEJMp1416014
- Morgan, C. J. A., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010). Cannabidiol attenuates the appetitive effects of delta-9-tetrahydrocannabinol in humans smoking their chosen cannabis. NeuropsychopharmacologyNeuropsychopharmacology, 35(9), 1879–1885. https://doi.org/https://doi.org/10.1038/npp.2010.58
- Morgan, C. J. A., Schafer, G. L., Freeman, T. P., & Curran, H. V. (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study. British Journal of Psychiatry, 197(4), 285–290. https://doi.org/https://doi.org/10.1192/bjp.bp.110.077503
- National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. The National Academies Press.
- Ramaekers, J. G., Kauert, G., van Ruitenbeek, P., Theunissen, E. L., Schneider, E., & Moeller, M. R. (2006). High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology, 31(10), 2296–2303. https://doi.org/https://doi.org/10.1038/sj.npp.1301068
- Rychert, M., Chris Wilkins, C., & Witten, K. (2018). “Lost in translation”: Issues with the establishment of a legal market for “low risk” psychoactive products (“legal highs”) in New Zealand. Drugs: Education, Prevention and Policy, 25(3), 254–261. https://doi.org/https://doi.org/10.1080/09687637.2017.1282422
- Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research, 130(1–3), 216–221. https://doi.org/https://doi.org/10.1016/j.schres.2011.04.017
- Sideris, A., Khan, F., Boltunova, A., Cuff, G., Gharibo, C., & Doan, L. V. (2018). New York physicians’ perspectives and knowledge of the State Medical Marijuana Program. Cannabis and Cannabinoid Research, 3(1), 74–84. https://doi.org/https://doi.org/10.1089/can.2017.0046
- Sloboda, Z., Stephens, R. C., Stephens, P. C., Grey, S. F., Teasdale, B., Hawthorne, R. D., Williams, J., & Marquette, J. F. (2009). The adolescent substance abuse prevention study: A randomized field trial of a universal substance abuse prevention program. Drug and Alcohol Dependence, 102(1–3), 1–10. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2009.01.015
- Stanton, R. (2019, April 7). Biggest Hash Bash ever: With pot legalized, rally draws huge crowd in Ann Arbor. MLive. https://www.mlive.com/news/ann-arbor/2019/04/biggest-hash-bash-ever-with-pot-legalized-rally-draws-huge-crowd-in-ann-arbor.html
- State of California Senate. (2017). SB-94 cannabis: Medicinal and adult use. Legislative Counsel’s Digest.
- van der Pol, P., Liebregts, N., de Graaf, R., Korf, D. J., van den Brink, W., & van Laar, M. (2013). Validation of self-reported cannabis dose and potency: An ecological study. Addiction, 108(10), 1801–1808. https://doi.org/https://doi.org/10.1111/add.12226